Medtronic, Inc.

Medtronic Ablation Frontiers LLC

Medtronics, Inc.

Medtronic Navigation, Inc.

Vinod Sharma

Eduardo N Warman

Xusheng Zhang

James D Reinke

Walter H Olson

Xiaohong Zhou

Robert W Stadler

Yong Kyun Cho

Shantanu Sarkar

Scott A Hareland

Vladimir Pavlovich Nikolski

Michael B Terry

Daniel C Sigg

Daniel L Hansen

Donna M Salmi

Barbara J Schmid

Paul Gordon Krause

Orhan Soykan

Todd M Zielinski

Brian Bruce Lee

Kevin T Ousdigian

Paul J DeGroot

Jiashu Li

Vasant Padmanabhan

Mark T Stewart

Dan Wittenberger

Karen J Kleckner

Randell Louis Werneth

James Kevin Carney

Troy Edward Jackson

Jonathan L Kuhn

Tommy Dean Bennett

Paul J Degroot

Teresa A Whitman

Timothy J Corvi

Andrew Radtke

Tom Dean Bennett

Joel R Lauer

Meleze Hocini

Michael T Lau

Jodi L Redemske

Michelle M Galarneau

Timothy H Robinson

Jeffery M Kramer

Amy C Dearking

Holly S Norman

Timothy G Laske

Douglas A Hettrick

Rahul Mehra

Can Cinbis

David A Anderson

Richard J O'Brien

Hank Bink

Tarek D Haddad

Jeffrey David Wilkinson

Erik J Peterson

Paul A Sobotka

Maneesh Shrivastav

Louis P Vera-Portocarrero

Xiaohong Qiu

Charles P Sperling

Deborah Ann Jaye

Yong-Fu Xiao

Cameron J Kaszas

Kevin L Wong

Lindsay M Streeter

Jennifer K Bravinder

Zhou Xiaohong

Brian A Duclos

A medical system including processing circuitry configured to assess a blood glucose level of a patient. The processing circuitry is configured to use a cardiac signal indicative of the electrical activity of the patient's heart and a temperature signal indicative of a body temperature of the patient. The cardiac signal may be, for example, an electrocardiogram (ECG), an electrogram (EGM), or another measure. The medical system is configured to determine a representative cardiac measure indicative of the cardiac signal and determine a representative temperature measure indicative of the temperature signal. The medical system is configured to assess when a blood glucose level of the patient may be outside a euglycemic range based on the representative cardiac measure and the representative temperature measure determined.

Cardiac and temperature monitor

In some examples, determining a heart failure status includes using an implantable medical device configured for subcutaneous implantation and comprising a plurality of electrodes and an optical sensor. Processing circuitry of a system comprising the device may determine, for a patient, a current tissue oxygen saturation value based on a signal received from the at least one optical sensor, a current tissue impedance value based on a subcutaneous tissue impedance signal received from the electrodes, and a current pulse transit time value based on a cardiac electrogram signal received from the electrodes and at least one of the signal received from the optical sensor and the subcutaneous tissue impedance signal. The processing circuitry may further compare the current tissue oxygen saturation value, current tissue impedance value, and current pulse transit time value to corresponding baseline values, and determine the heart failure status of the patient based on the comparison.

Sensing for heart failure management

Provided is a method, system and/or apparatus for determining prospective heart failure event risk. Acquired from a device memory are a heart failure patient's current and preceding risk assessment periods. Counting detected data observations in the current risk assessment period for a current risk assessment total amount and counting detected data observations in the preceding risk assessment period for a preceding risk assessment period total amount. Associating the current risk assessment and preceding risk assessment total amounts with a lookup table to acquire prospective risk of heart failure (HF) event for the preceding risk assessment period and the current risk assessment period. Employing weighted sums of the prospective risk of the HF event for the preceding risk assessment period and the current risk assessment period to calculate a weighted prospective risk of the HF event for a patient. Displaying on a graphical user interface the weighted prospective risk of the HF event for the patient.

Using biomarker information for heart failure risk computation

A system includes a processor and a memory storing instructions thereon. The instructions, when executed by the processor, cause the processor to: infuse a substance into a target object, via an infusion device, according to a first flow rate; set a second flow rate associated with infusing the substance into the target object, based on a withdrawal rate of the infusion device from the target object; and infuse the substance into the target object based on the second flow rate.

Robotically-assisted drug delivery

An implantable medical system includes an implantable catheter advanceable into a coronary sinus of a patient's heart. A guide element and an implantable lead receivable in the side lumen is advanceable through an angled opening of the catheter to be deflected laterally away from the catheter at the deflection angle to position the at least one testing electrode or at least one pacing electrode, respectively, in a myocardium of the patient's heart when the distal portion of the catheter is positioned in the coronary sinus.

Coronary sinus conduction system pacing and delivery

A method of operation of a medical device system for determining prospective heart failure hospitalization risk. The method includes measuring one or more data observations via one or more electrodes of an implanted medical device disposed in a patient's body. The data observations are stored into memory of the implantable medical device of a patient. The data observations are transmitted to an external device. The processor of the external device parses the data observations into one or more evaluation periods. Using the number of observations in one or more evaluation periods, a look up table, stored into memory of the external device, is accessed. The look up table associates prospective heart failure hospitalization risk with the data observations noted in the evaluation period. One or more embodiments involve a weighted prospective heart failure hospitalization risk for the set of evaluation periods. The prospective heart failure hospitalization is then displayed on the graphical user interface.

Determining prospective risk of heart failure hospitalization

An example method of cycling electric stimulation includes delivering, via an implantable device, electric stimulation to a patient in accordance with a first therapy program; monitoring, via the implantable device and while the electric stimulation is being delivered in accordance with the first therapy program, a biomarker; and responsive to determining the biomarker satisfies a threshold, delivering, via the implantable device, electric stimulation to the patient in accordance with a second therapy program that is different than the first therapy program.

Electric stimulation system

An implantable medical device comprises a sensing module configured to obtain electrical signals from one or more electrodes and a control module configured to process the electrical signals from the sensing module in accordance with a tachyarrhythmia detection algorithm to monitor for a tachyarrhythmia. The control module detects initiation of a pacing train delivered by a second implantable medical device, determines a type of the detected pacing train, and modifies the tachyarrhythmia detection algorithm based on the type of the detected pacing train.

Implantable cardioverter-defibrillator (ICD) tachyarrhythmia detection modifications responsive to detected pacing

A method and device apparatus to deliver a pacing therapy capable of remodeling a patient's heart over a period of time that includes monitoring one or more parameters in response to a delivered cardiac remodeling pacing, determining whether the cardiac remodeling pacing has an effect on cardiac normalization in response to the monitoring, and adjusting the cardiac remodeling pacing in response to the determined effect on cardiac normalization. The method and device may also perform short-term monitoring of one or more parameters in response to the delivered cardiac remodeling pacing, monitor one or more long-term parameter indicative of a long-term effect of the delivered cardiac remodeling pacing, determine the long-term effect of the delivered cardiac remodeling pacing on cardiac normalization in response to the monitoring, and adjust the cardiac remodeling pacing in response to one or both of the short-term monitoring and the determined long-term effect on cardiac normalization.

Delivery of cardiac pacing therapy for cardiac remodeling

Methods and systems for seamless adjustment of treatment are disclosed. A determination is made as to whether to intervene with a patient's treatment. Implanted device memory data is acquired over a pre-specified time period. Risk status is determined from the device memory data. Another external device memory data is acquired over a pre-specified time period. A determination is made as to whether to adjust treatment of the patient in response to the risk status, the data acquired from the implanted device memory and the external device memory data.

Medical system for seamless therapy adjustment

In situations in which an implantable medical device (e.g., a subcutaneous ICD) is co-implanted with a leadless pacing device (LPD), it may be important that the subcutaneous ICD knows when the LPD is delivering pacing, such as anti-tachycardia pacing (ATP). Techniques are described herein for detecting, with the ICD and based on the sensed electrical signal, pacing pulses and adjusting operation to account for the detected pulses, e.g., blanking the sensed electrical signal or modifying a tachyarrhythmia detection algorithm. In one example, the ICD includes a first pace pulse detector configured to obtain a sensed electrical signal and analyze the sensed electrical signal to detect a first type of pulses having a first set of characteristics and a second pace pulse detector configured to obtain the sensed electrical signal and analyze the sensed electrical signal to detect a second type of pulses having a second set of characteristics.

Pace pulse detector for a medical device

Techniques are disclosed for using a cardiac signal sensed via a plurality of electrodes disposed on one or more leads implanted within an epidural space of a patient to control spinal cord stimulation (SCS) therapy. In one example, an implantable medical device (IMD) senses an electrical signal via a plurality of electrodes disposed on one or more leads implanted within an epidural space of a patient. Processing circuitry determines, from the electrical signal, one or more cardiac features indicative of activity of a heart of the patient. The processing circuitry controls, based on the one or more cardiac features, delivery of SCS therapy to the patient.

Sensing cardiac signals with leads implanted in epidural space

Methods and systems for seamless adjustment of treatment are disclosed. A determination can be made as to whether to intervene with a patient's treatment based on data obtained from implantable electrodes and/or non-implantable electrodes. The data from non-implantable electrodes have a correction factor applied to adjust for less accuracy compared to data acquired from implantable electrodes.

Medical system for therapy adjustment

A health care system acquires data determines whether a patient is at risk of hypervolemia or hypovolemia. The method comprises (a) acquiring from a device memory a patient's absolute intrathoracic impedance data over a pre-specified time period, (b) determining a running average of the intrathoracic impedance data over the pre-specified time period, and (c) determining by the system whether the running average of the intrathoracic impedance data over the pre-specified time period exceeds one of a first and second range, the first range being a higher value boundary of intrathoracic electrical impedance and the second range being a lower value boundary of intrathoracic electrical impedance.

Absolute intrathoracic impedance based scheme to stratify patients for risk of a heart failure event

Growing community of inventors

Blaine, MN, United States of America

Vinod Sharma